Weekly shot may help teens and adults with severe hemophilia move better

NCT ID NCT05817812

First seen Nov 01, 2025 · Last updated May 07, 2026 · Updated 23 times

Summary

This study is testing a new medicine called efanesoctocog alfa in about 90 people aged 12 and older with severe hemophilia A. Participants receive a weekly injection for 24 months. The goal is to see if this treatment helps them be more physically active and improves joint health. The study uses activity trackers and diaries to track bleeds, pain, and quality of life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMOPHILIA A, SEVERE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Investigational Site

    Vienna, Austria

  • Investigational Site

    Zagreb, Croatia

  • Investigational Site

    Brno, Czechia

  • Investigational Site

    Prague, Czechia

  • Investigational Site

    Bordeaux, France

  • Investigational Site

    Le Kremlin-Bicêtre, France

  • Investigational Site

    Marseille, France

  • Investigational Site

    Strasbourg, France

  • Investigational Site

    Berlin, Germany

  • Investigational Site

    Frankfurt, Germany

  • Investigational Site

    Giessen, Germany

  • Investigational Site

    Hamburg, Germany

  • Investigational Site

    Athens, Greece

  • Investigational Site

    Dublin, Ireland

  • Investigational Site

    Catanzaro, Italy

  • Investigational Site

    Florence, Italy

  • Investigational Site

    Naples, Italy

  • Investigational Site

    Parma, Italy

  • Investigational Site

    Rome, Italy

  • Investigational Site

    Utrecht, Netherlands

  • Investigational Site

    Oslo, Norway

  • Investigational Site

    Ljubljana, Slovenia

  • Investigational Site

    Barcelona, Spain

  • Investigational Site

    Madrid, Spain

  • Investigational Site

    Oviedo, Spain

  • Investigational Site

    Lund, Sweden

  • Investigational Site

    Solna, Sweden

  • Investigational Site

    Canterbury, United Kingdom

  • Investigational Site

    Newcastle upon Tyne, United Kingdom

  • Investigational Site

    Oxford, United Kingdom

Conditions

Explore the condition pages connected to this study.